⌘K
Loading ticker…
ImmunityBio, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, ImmunityBio, Inc. Common Stock (IBRX) has a 3-month relative strength percentile of 69 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 91. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 6.5%, relative volume 3.41×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
69 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
IBRX is in a stage 2 uptrend, week 1. Currently in a 85-day base; basing ADR 8.3% (broad 9.9%). VCP detected: 5 contractions. RS line below base-start high. Distance from 50d / 200d: 14.9% / 65.3%.
No attention data for this ticker yet — it joins the daily scan once a baseline builds.
IBRX is held by 8 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $87M notional. Top 3 carry $229M.
Top 8 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $87M |
| XBIState Street SPDR S&P Biotech ETF | 1.06% | $79M |
| VBVanguard Small Cap ETF | 0.04% | $64M |
| IWMiShares Russell 2000 ETF | 0.08% | $55M |
| VBKVanguard Small-Cap Growth ETF | 0.09% | $36M |
| VXFVanguard Extended Market ETF | 0.03% | $26M |
| IWOiShares Russell 2000 Growth ETF | 0.13% | $15M |
| ITOTiShares Core S&P Total U.S. Stock Market ETF | 0.00% | $3M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | IBRX Jan avg: 48.08% median: 4.86% win: 50% σ: 115.75% n: 4 2022-04-12 → 2026-05-29 | IBRX Feb avg: 14.21% median: 18.07% win: 50% σ: 42.22% n: 4 2022-04-12 → 2026-05-29 | IBRX Mar avg: -10.49% median: -15.04% win: 25% σ: 17.57% n: 4 2022-04-12 → 2026-05-29 | IBRX Apr avg: 10.45% median: -7.43% win: 40% σ: 37.95% n: 5 2022-04-12 → 2026-05-29 | IBRX May avg: -1.19% median: 3.58% win: 60% σ: 10.79% n: 5 2022-04-12 → 2026-05-29 | IBRX Jun avg: -0.57% median: -0.91% win: 25% σ: 1.16% n: 4 2022-04-12 → 2026-05-29 (current) | IBRX Jul avg: -10.41% median: -12.67% win: 25% σ: 11.72% n: 4 2022-04-12 → 2026-05-29 | IBRX Aug avg: -13.04% median: -14.09% win: 25% σ: 14.30% n: 4 2022-04-12 → 2026-05-29 | IBRX Sep avg: 7.13% median: 5.05% win: 75% σ: 12.51% n: 4 2022-04-12 → 2026-05-29 | IBRX Oct avg: 33.52% median: 25.36% win: 75% σ: 39.12% n: 4 2022-04-12 → 2026-05-29 | IBRX Nov avg: 3.11% median: -0.74% win: 50% σ: 9.50% n: 4 2022-04-12 → 2026-05-29 | IBRX Dec avg: -9.22% median: -12.04% win: 25% σ: 35.26% n: 4 2022-04-12 → 2026-05-29 |